[Experimental study on glibenclamide (HB 419), a new particularly active hypoglycaemic sulphonamide. II. Betacytotrophic action and stimulation of the neogenesis of the islets of Langerhans].
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004285:Dogs; D005260:Female; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000096:biosynthesis / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development*; D051379:Mice
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin
Etude expérimentale d'un nouveau sulfamide hypoglycémiant particulièrement actif, le HB 419 ou glibenclamide. II. Action bêtacytotrophe et stimulatrice de la néogénèse des îlots de langerhans.